International Journal of Hematology and Oncology
2023, Vol 33, Num 4 (Special Issue) Page(s): 022-024
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
The Management of Second Generation Thyrosine Kinase Inhibitors Treatment: Case Report
Selda KAHRAMAN1, Ozden PISKIN1, Mehmet Ali OZCAN1
Dokuz Eylul University Faculty of Medicine, Department of Hematology, Izmir, TURKEY
Keywords: CML, Imatinib failure, Dasatinib, Cytogenetic remission
The current management of chronic myeloid leukemia (CML) is dependent upon chronic thyrosine kinase inhibition (TKI). Several drugs have been developed for tyrosine kinases during the last decade. Imatinib mesylate (IM) is the first molecular targeting TKI. IM is the current ‘standard- of -care’ in CML patients to obtain cytogenetic remission. Patients refractory to IM can be treated with second generation TKI including dasatinib. The aim of this case report is to assess the efficacy of dasatinib treatment in the basis of IM failure.
Selda KAHRAMAN1, Ozden PISKIN1, Mehmet Ali OZCAN1
Dokuz Eylul University Faculty of Medicine, Department of Hematology, Izmir, TURKEY
Keywords: CML, Imatinib failure, Dasatinib, Cytogenetic remission
The current management of chronic myeloid leukemia (CML) is dependent upon chronic thyrosine kinase inhibition (TKI). Several drugs have been developed for tyrosine kinases during the last decade. Imatinib mesylate (IM) is the first molecular targeting TKI. IM is the current ‘standard- of -care’ in CML patients to obtain cytogenetic remission. Patients refractory to IM can be treated with second generation TKI including dasatinib. The aim of this case report is to assess the efficacy of dasatinib treatment in the basis of IM failure.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |